Users of Ozempic, Wegovy and other GLP-1s have been issued with a warning over a potential eyesight risk which prompted changes to labelling.
The U.S. Food and Drug Administration (FDA) has mandated safety label updates for the medications like Ozempic and Wegovy to reflect a potential link to non-arteritic anterior ischemic optic neuropathy (NAION).
This is a rare and serious condition also known as an 'eye stroke' and can cause permanent vision loss.